Thermo Fisher Scientific Inc.: Form 10-Q for the period ended Jun 28, 2025
Filed with the SEC on Aug 1, 2025 and accepted by EDGAR at Aug 1, 2025, 10:41 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2025-06-28. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2025-03-30 to 2025-06-28 | $10.86bn | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 6 months2025-01-01 to 2025-06-28 | $21.22bn | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Research and development | 3 months2025-03-30 to 2025-06-28 | $352.0m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months2025-01-01 to 2025-06-28 | $695.0m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months2025-03-30 to 2025-06-28 | $2.14bn | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 6 months2025-01-01 to 2025-06-28 | $4.22bn | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months2025-03-30 to 2025-06-28 | $1.83bn | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months2025-01-01 to 2025-06-28 | $3.55bn | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2025-03-30 to 2025-06-28 | $404.0m | us-gaap:InterestExpenseNonoperating |
| Interest expense | 6 months2025-01-01 to 2025-06-28 | $707.0m | us-gaap:InterestExpenseNonoperating |
| Income tax | 3 months2025-03-30 to 2025-06-28 | $92.0m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 6 months2025-01-01 to 2025-06-28 | $187.0m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2025-03-30 to 2025-06-28 | $1.62bn | us-gaap:NetIncomeLoss |
| Net income | 6 months2025-01-01 to 2025-06-28 | $3.12bn | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2025-03-30 to 2025-06-28 | $4.28 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 6 months2025-01-01 to 2025-06-28 | $8.26 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2025-03-30 to 2025-06-28 | $4.28 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months2025-01-01 to 2025-06-28 | $8.27 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2025-03-30 to 2025-06-28 | 378,000,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months2025-01-01 to 2025-06-28 | 378,000,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 6 months2025-01-01 to 2025-06-28 | $2.12bn | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months2025-01-01 to 2025-06-28 | $656.0m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Dividends paid | 6 months2025-01-01 to 2025-06-28 | $311.0m | us-gaap:PaymentsOfDividendsCommonStock |
| Share repurchases | 6 months2025-01-01 to 2025-06-28 | $2.00bn | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | At period end2025-06-28 | $4.58bn | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2025-06-28 | $24.58bn | us-gaap:AssetsCurrent |
| Total assets | At period end2025-06-28 | $101.23bn | us-gaap:Assets |
| Current liabilities | At period end2025-06-28 | $12.72bn | us-gaap:LiabilitiesCurrent |
| Long-term debt | At period end2025-06-28 | $35.03bn | us-gaap:LongTermDebt |
| Current portion of debt | At period end2025-06-28 | $2.21bn | us-gaap:DebtCurrent |
| Shareholders' equity | At period end2025-06-28 | $50.51bn | us-gaap:StockholdersEquity |
| Shares outstanding | At period end2025-06-28 | 377,612,121 shares | dei:EntityCommonStockSharesOutstanding |
Source: SEC EDGAR, the filing index for accession 0000097745-25-000101. Last ingested by Listed: Nov 6, 2026, 03:40 ET. Listed shows no prices and gives no investment advice.